Kornimate/medical-research-clean huggingface dataset:
development and validation of the prediction model for cognitive impairment

Conditions: Stroke, Acute

Summary: according to the "chinese stroke report" released in 2020, the incidence of stroke in china is 1114.8/100,000, acute ischemic stroke (ais) accounts for 70% to 80% of the total number of stroke population, and elderly stroke patients are up to 2/3. about 1/3 of stroke patients would experience post-stroke cognitive impairment (psci), which seriously affected patients' quality of life and survival time, and increases disease and economic burden. therefore, early identification, assessment, prevention and intervention of psci, and improvement of patients' quality of life and prognosis have become the focus of clinical research. this is a prospective cohort study. we intend to: (1) continuously collect elderly ais patients who will be admitted to the department of neurology, the department of rehabilitation and the department of gerontology of shenzhen second people's hospital from 2022 year to 2024 year; (2) collect baseline and follow-up data, and build a prediction model for cognitive impairment in elderly ais patients; (3) internal validation using bootstrap model; (4) collect the data of the elderly ais patients who will be admitted to shenzhen longhua district people's hospital andshenzhen longgang central hospital, and conduct external validation; (5) evaluate the predictive efficacy of the model.

this study consists of two parts. the first part is to develop a predictive model for cognitive impairment in elderly patients with acute ischemic stroke. continuously collect the baseline data and follow-up data of elderly ais patients admitted to the shenzhen second people's hospital from september 2022 to december 2023, including general demographic data, laboratory examination indicators, imaging indicators and assessment scales. take the occurrence of psci as the dependent variable and the risk factors of psci in elderly ais patients will be analyzed. multivariate cox regression will be used to develop a prediction model for cognitive impairment in elderly ais patients. the second part is to do clinical evaluation of prediction model of cognitive impairment in elderly patients with acute ischemic stroke. bootstrap method will be used for internal validation of the model. continuously collect the data of elderly ais patients from january 2024 to december 2024 from the other two hospitals in guangdong province, china. externally validate the model and evaluate the clinical application effect of psci prediction model in elderly ais patients using c-index, reclassification index, calibration curve, time-dependent roc curve and other indicators. finally, the model is presented by nomogram.

Eligibility criteria:
inclusion criteria: 1. patients age 60 years or older. 2. stroke occurring within 7 days. 3. meet the diagnostic criteria of chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018. 4. informed consent. exclusion criteria: 1. incomplete main clinical data; 2. patients with transient ischemic attack; 3. patients had cognitive dysfunction before enrollment.
effects of aripiprazole on cocaine craving and self-administration

Conditions: Cocaine Abuse

Summary: the purpose of this study is to investigate whether aripiprazole will decrease cocaine self-administration, subjective effects and cravings compared to placebo.

despite the recent increase in data about cocaine's basic neurochemical mechanisms of action, progress towards the development of an effective pharmacological treatment for cocaine abuse has been disappointing. we are proposing to use our laboratory model of repeated dose cocaine self-administration to assess the potential efficacy of the novel antipsychotic, aripiprazole. aripiprazole is a partial agonist at both the dopamine d2 receptor and at the serotonin 5ht1a receptor, while antagonizing the 5ht2a receptor. by functioning as a partial d2 agonist, aripiprazole is hypothesized to function as a d2 antagonist during hypodopaminergic states, such as during cocaine use, while functioning as a d2 agonist during hypodopaminergic states, such as during cocaine withdrawal. this 42-day, outpatient/inpatient/outpatient/inpatient protocol will evaluate the effects of aripiprazole maintenance (0, 15 mg/day) on cocaine craving, subjective effects, and self-administration using a within-subjects design. non-treatment seeking cocaine abusers will be maintained outpatient for 16 days of dose maintenance prior to inpatient cocaine self-administration sessions. during the inpatient phases, volunteers will live on a hospital clinical research unit and will participate in laboratory sessions in which they will have the opportunity to choose between repeated doses of smoked cocaine and $5. in addition to measuring their cocaine self-administration, we will measure the cardiovascular and subjective effects of cocaine under each aripiprazole maintenance condition.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for current cocaine abuse * average use of smoked cocaine is at least 2x/week for past 6 mos); currently spends at least $70 per week on cocaine * has patterns of smoked cocaine use in terms of frequency and amounts which parallel or exceed those administered in the study * age 21-45 * able to give informed consent, and comply with study procedures exclusion criteria: * current seizure disorder, heart disease or psychiatric disorders (other than cocaine dependence) * dependence on substances other than cocaine or nicotine * request for drug treatment * judged to be noncompliant with study protocol * current use of any medication that has the potential to interact with aripiprazole (i.e., seizure medications, anti-fungal medications, cardiac medications, or medication that produces drowsiness) * clinical laboratory tests outside normal limits that are clinically unacceptable to the study physician (bp \> 140/90; bun, creatinine, lfts \> 1.5 uln; hematocrit \< 34 for women, \< 36 for men; pseudocholinesterase deficiency) * currently meeting dsm-iv criteria for all major psychiatric/psychotic disorders other than transient psychosis due to drug abuse * current parole or probation * history of significant violent or suicidal behavior

Keywords: aripiprazole cocaine abuse
hemofiltration for contrast-induced nephropathy

Conditions: Chronic Kidney Disease; Cardiac Catheterization

Summary: contrast-induced acute renal failure can be prevented with hemofiltration which is performed during cardiac catheterization


Eligibility criteria:
inclusion criteria: * patients with serum creatinine\>2.0mg/dl and/or gfr\<50ml/min exclusion criteria: * emergent cardiac catheterization * patients on chronic dialysis * patients with hyha\>iii heart failure
distal radius fracture prospective database 50-80 years old

Conditions: Radius Fracture Distal

Summary: the problem distal radius fractures (drf) are common and result in a variable amount of disability. the investigators have completed considerable work in developing tools that measure impairment and disability after drf . the investigators initial studies indicate that the associated disablement process is multifactorial and variable with only 25% of the resultant disability predicted by baseline patient and injury characteristics. the investigators see drf as a signal event where some people are at-risk of transitioning from an active lifestyle to inactivity and subsequent health risks. the investigators recent data confirms variable participation following a drf. the traditional focus in orthopedic/rehabilitative approaches to drf fracture management has been localized to the wrist, largely ignoring this potential transition and its health impacts. the investigators will initiate a line of investigation that will profile the at-risk older adult who presents with a drf with the ultimate goal of accurate identification and prevention of adverse activity transitions (active to inactive). in this study the investigators will identify the extent of the problem by quantifying changes in activity/participation and its short-term health impacts. the investigators will also identify the risk factors present at time of injury that predict a loss of mobility/activity/participation. this work has the potential to identify tools and/or clinical prediction rules that identify at-risk individuals at a critical time where early intervention might most easily prevent adverse outcomes associated with inactivity.


Eligibility criteria:
inclusion criteria: individuals 50-80 years old * one month of fracture resulting from a fall from standing height or less will be recruited through our orthopedic surgeon * wrist fracture exclusion criteria: previous history of humeral, hip or vertebral fracture • testing will not be performed on patients with evident postural instability, severe chronic conditions (parkinson's disease) or other vestibulo-ocular abnormalities.

Keywords: distal radius fracture condition risk factors adverse activity transitions following drf optimal assessment approach
comparing effects of conventional neurorehabilitation with exoskeleton with high-intensity gait training

Conditions: Stroke; Gait, Hemiplegic

Summary: the purpose of this research is to compare improvements between the rehab intervention with walking practice using the robotic exoskeleton versus walking practice that is vigorous enough to keep participants' heart rate over a certain target level during physical therapy sessions. investigators want to compare improvements in your walking function and mental health that occur after 20 interventions. the study also aims to evaluate if participants' mental health, social support, and health literacy affect attendance at physical therapy sessions.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * english or spanish-speaking * a diagnosis of stroke (intracerebral hemorrhage or acute ischemic stroke) * referred to good shepherd rehabilitation outpatient physical therapy clinic exclusion criteria: * unable to follow 1-step commands * \> 220 pounds (100 kg) * height \ 6'4" * unable to take a few steps with assistance * a score of ≥ 50/56 on berg balance scale (bbs) * a score of ≥ 26/30 on functional gait assessment (fga) * resting blood pressure \>180/110 mmhg * resting heart rate \> 120 bpm * severe cardiac disease (new york heart association classification iv) * severe spasticity (modified ashworth score \> 3) * unstable spine or unhealed pelvic/limb fractures * active heterotrophic ossification impacting lower extremity range of motion * significant lower or upper extremity contractures * inability to achieve neutral ankle dorsiflexion with 12° of knee flexion * pregnancy * colostomy * poor skin integrity in areas in contact with the eksogttm * unresolved deep vein thrombosis * lower limb prosthesis or amputation * leg length discrepancies \> 0.5 inches for upper legs, 0.75 inches for lower legs * rom restrictions preventing normal, reciprocal gait * inability to stand for \> 3 minutes due to pain or orthostatic hypotension * pusher syndrome * cortical blindness

Keywords: health literacy balance compliance to therapy gait function high intensity gait training exoskeleton
the clinical character，risk and prognosis of post-neurosurgical intracranial infection with different pathogens.

Conditions: Intracranial Infections; Ventriculitis; Meningitis; Gram-Positive Bacterial Infections; Gram-Negative Bacterial Infections; Neurosurgery

Summary: intracranial infection is one of the common clinical complications after neurosurgery, especially after external cerebrospinal fluid drainage. postoperative intracranial infection has a very high incidence, and its incidence is about 0.34%-3.1%. once infection occurs, it will directly affect the length of hospitalization, mortality and disability of postoperative patients. the pathogenic bacteria of postoperative intracranial infections include g-bacteria and g+ bacteria, and fungi. common g+ bacteria are staphylococcus aureus. common g-bacteria are acinetobacter baumannii, klebsiella pneumoniae, and pseudomonas aeruginosa bacteria, escherichia coli and so on. in recent years, studies have reported that postoperative intracranial infections of g-bacteria are gradually increasing. in the previous study of our research group, it was found that acinetobacter baumannii and klebsiella pneumoniae accounted for the top two pathogens of postoperative intracranial infections in icu. in particular, the proportion of carbapenem-resistant g-bacteria has increased, which brings difficulty and challenge to the treatment and seriously affects the prognosis of patients. different pathogen infections may lead to different prognosis of patients with intracranial infection after neurosurgery. with different pathogens as the starting point, there are few studies comparing the clinical features, risk factors, and prognosis of intracranial infections after neurosurgery. therefore, it is great significant to explore and understand different pathogenic bacteria, risk factors, drug resistance, treatment options, and prognosis after neurosurgery.

1. to study the epidemiological distribution of pathogenic bacteria of intracranial infection after neurosurgery. 2. to study the risk factors of intracranial infection after neurosurgery (operations, type of external drainage tube, days of drainage tube , etc.). 3. to compare differences in clinical character，risks , treatment options, prognostic indicators between g+ bacterial infection group and g-infected bacterial group after neurosurgery.

Eligibility criteria:
inclusion criteria: - patients diagnosed with intracranial infection after surgery and positive pathogenic microorganisms cultured in cerebrospinal fluid exclusion criteria: * (1) \< 18 years old, (2) pregnant or lactating women, (3) fungus in csf culture, (4) clinical judgment is not intracranial infection, and csf culture positive considers contaminating patients.
a trial to investigate the efficacy and safety of orally administered tolvaptan (opc-41061) in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration

Conditions: Chronic Renal Failure

Summary: this is a study to investigate the efficacy and safety of opc-41061 by 24-week oral administration of opc-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration and who have daily urine volume of at least 500 ml/day.


Eligibility criteria:
inclusion criteria: * chronic renal failure requiring hemodialysis or hemodiafiltration 3 times a week * daily urine volume of ≥ 500 ml/day * male or female patients age 20 to 80 years, inclusive * use of one of the specified contraceptive methods until 4 weeks after final imp administration * capable of providing their own written informed consent prior to any trial-related procedures being performed exclusion criteria: * patients with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause * patients with nyha class iv heart failure * patients with impaired hepatic function(chronic hepatitis, drug-induced liver injury) * patients with serious ischemic heart disease who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial * patients with serious arrhythmia who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial * patients with serious secondary hyperparathyroidism(intact parathyroid hormone \> 500 pg/ml) * patients who are concomitantly undergoing peritoneal dialysis * patients with a history of cerebrovascular disease or coronary artery disease within 4 weeks prior to informed consent, a history of hypersensitivity to any ingredient of tolvaptan or benzazepine derivatives such as mozavaptan hydrochloride or a history of impaired hepatic function(chronic hepatitis, drug-induced liver injury) * patients with any of the following abnormal laboratory values: hemoglobin \ 3.0 mg/dl, alt (gpt) or ast (got) \> 2 times the upper limit of the reference range, serum sodium \> upper limit of the reference range, serum sodium \ 6.0 meq/l * patients who are unable to sense thirst or who have difficulty with fluid intake * patients who have received opc-41061 in history. * participation in any other clinical trial or post-marketing clinical study within 4 weeks prior to informed consent for the present trial * female patients who are pregnant, possibly pregnant, or nursing * patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial

Keywords: undergoing hemodialysis undergoing hemodiafiltration
efficacy evaluation of hydrolyzed collagen peptide on knees, hips, and ankle pain in osteoarthritis

Conditions: Pain, Joint

Summary: the aim of this study is to evaluate the effectiveness of hydrolyzed collagen peptides on joint pain, stiffness and physical function in adults with osteoarthritis who have complaints on knee joints together with hip and ankles. the assessment of improvements on volunteers' quality of life, and safety and tolerability of the product is the other objective of this placebo-controlled, randomized study.


Eligibility criteria:
inclusion criteria: 1. male and female individuals with osteoarthritis on knee who are aged between 45-60 years old, 2. who are not drug-naïve to osteoarthritis and related conditions, 3. volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements, 4. volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: sbp within 100 to 140 mmhg, dbp within 60 to 90 mmhg and hr within 50 to 100 bpm at least after 5 minutes of rest, 5. volunteers who have understanding of the study and agreement to give a written informed consent. exclusion criteria: 1. who have atopic constitution or asthma and/or known allergy for bovine derived collagen products and/or other any of the excipients of the product. 2. who have hereditary problems of galactose intolerance, the lapp lactase deficiency or glucosegalactose malabsorption. 3. who have an active rheumatoid arthritis or any other inflammatory arthritic condition that researchers consider non appropriate. 4. who have diabetes mellitus. 5. who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study. 6. who have current participation in another clinical study, or participation in a relevant study within 3 months. 7. who have any history or presence of serious or life-threatening conditions of cardiovascular, neurological, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria. 8. who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy. 9. who are planned to go or already went under a joint-related reconstructive surgery, 10. for female volunteers, who had undergone, or planned to undergo, pregnancy or breastfeeding. 11. who have current or regular intake of nsaids, contraceptives, hormones, obesity drugs, absorption inhibitors or antidepressants 12. who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment. 13. who have history of drug abuse. 14. who have relationship to the investigator. 15. who are not suitable to any of inclusion criteria. 16. who have history of difficulty of swallowing.
p16ink4a in bronchopulmonary dysplasia in children

Conditions: Bronchopulmonary Dysplasia

Summary: the bronchopulmonary dysplasia (bpd) is a respiratory disease of the premature child which lead to a reduction of gas exchange surface and to a prolonged respiratory failure. this disease has morphologic and functional consequences at adulthood and is today considered to be an early determinant of respiratory diseases at adulthood. the physiopathology of bpd is not well known. several mechanisms could be involved especially a reparation failure favored by an increase of cellular senescence which is a permanent stop of cellular proliferation. the transcription factor 16 ink4a, considered as a marker of aging, is one of the essential markers of senescence. its increase during prematurity was shown at the blood cells of the cordon, but its involvement in bpd and its evolution in child are not yet studied.


Eligibility criteria:
inclusion criteria: premature(\< 28 ga) neonates * alive neonate born at less than 28 gestational age * signed inform consent term neonates: * alive neonate born at least at 37 ga or more * signed inform consent child from 7 to 15 years old with bpd: * child from 7 to 15 years old * child with a bpd diagnosed * signed inform consent child from 7 to 15 years old without bpd: * child from 7 to 15 years old * child receiving a blood test * signed inform consent exclusion criteria: premature (\< 28 ga) and term neonates: -congenital malformation child from 7 to 15 years old with bpd: * cystic fibrosis * evolutive cancer * chronic inflammatory disease * known anemia * refusal of participation of child or parental authority child from 7 to 15 years old without bpd: * other respiratory disease: severe asthma, cystic fibrosis, deficit aat, bronchial dilatation * evolutive cancer * chronic inflammatory disease * known anemia * refusal of participation of child or parental authority
a dose escalation and expansion trial with byon4228 alone and in combination in patients with advanced or metastatic solid tumors

Conditions: Solid Tumor

Summary: this is a phase i trial with byon4228, a humanized monoclonal antibody (mab) directed against signal regulatory protein (sirp)α in solid tumors, alone and in combination with pembrolizumab.

this study includes a dose escalation part (part 1) in which the mtd or obd and rde(s) will be determined. this trial includes an expansion part (part 2) to evaluate efficacy and safety of byon4228 in combination with pembrolizumab in specific patient cohorts. byon4228 is a humanized igg1 mab directed against sirpα. byon4228 binds sirpα expressed on innate immune cells, especially monocytes, macrophages and neutrophils. byon4228 blocks binding of sirpα to cd47 and inhibits signaling through the cd47-sirpα axis.

Eligibility criteria:
inclusion criteria: * patient with histologically confirmed, locally advanced or metastatic cancer who has progressed on standard therapy or for whom no standard therapy exists: * part 1 (dose escalation): solid tumors of any origin; * part 2 (expansion): patients with other solid tumor types indicated for pembrolizumab monotherapy; * eastern cooperative oncology group (ecog) performance status ≤ 1; * for part 2 only: at least one measurable cancer lesion as defined by the response evaluation criteria for solid tumors (recist version 1.1); * adequate baseline organ function. exclusion criteria: * having been treated with cd47 or sirpα targeting agents or other anticancer therapy within 4 weeks prior to the start of imp treatment; * history of hypersensitivity or allergic reaction to any of the excipients of byon4228; * any contraindication to pembrolizumab treatment; * for part 2: patients previously given a pd-1 or pd-l1 inhibitor who had subsequent disease progression within 8 weeks of initiation; * symptomatic brain metastases; * history of autoimmune disorders; * severe active infection or other severe uncontrolled systemic disease; * having clinically significant cardiovascular disease; * known infection of hepatitis b, c or e. key inclusion and exclusion criteria details are listed here, additional requirements may apply.

Keywords: mab monoclonal antibody sirpα cd47 sirp